312 related articles for article (PubMed ID: 7492796)
1. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
2. Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Schultz KR; Bader S; Nelson D; Wang MD; HayGlass KT
Transplantation; 1997 Oct; 64(7):1055-65. PubMed ID: 9381529
[TBL] [Abstract][Full Text] [Related]
3. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
Schultz KR; Paquet J; Bader S; HayGlass KT
Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
Fujii H; Ivison SM; Shimizu H; Kajiwara R; Kariminia A; Yan M; Dutz JP; Schultz KR
Biol Blood Marrow Transplant; 2012 Apr; 18(4):546-56. PubMed ID: 22178962
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production.
Schultz KR; Su WN; Hsiao CC; Doho G; Jevon G; Bader S; MacFarlane DE; Gilman AL
Biol Blood Marrow Transplant; 2002; 8(12):648-55. PubMed ID: 12523576
[TBL] [Abstract][Full Text] [Related]
6. The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.
Schultz KR; Gilman AL
Leuk Lymphoma; 1997 Jan; 24(3-4):201-10. PubMed ID: 9156650
[TBL] [Abstract][Full Text] [Related]
7. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
8. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
9. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
[TBL] [Abstract][Full Text] [Related]
11. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
12. Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Hsiao CC; Su WN; Forooghian F; Bader S; Rempel J; HayGlass KT; Gilman A; Schultz KR
Bone Marrow Transplant; 2002 Dec; 30(12):905-13. PubMed ID: 12476284
[TBL] [Abstract][Full Text] [Related]
13. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
14. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.
Schlegel PG; Aharoni R; Chen Y; Chen J; Teitelbaum D; Arnon R; Sela M; Chao NJ
Proc Natl Acad Sci U S A; 1996 May; 93(10):5061-6. PubMed ID: 8643529
[TBL] [Abstract][Full Text] [Related]
15. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease.
Duffner UA; Maeda Y; Cooke KR; Reddy P; Ordemann R; Liu C; Ferrara JL; Teshima T
J Immunol; 2004 Jun; 172(12):7393-8. PubMed ID: 15187116
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
19. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
